Prokarium
Prokarium is a clinical-stage biopharmaceutical company headquartered in London, UK, developing bacterial immunotherapies for solid tumors. Its foundational technology uses a proprietary attenuated strain of Salmonella enterica serovar Typhi (ZH9) as a microbial immunotherapy platform that is naturally tumor-targeting and oncolytic, designed to overcome the suppressive tumor microenvironment and generate anti-tumor immune responses while enabling diverse cargo delivery. The lead program, ZH9 for non-muscle invasive bladder cancer, is in the Phase 1/1b PARADIGM-1 trial, with a muscle-invasive bladder cancer combination arm alongside checkpoint inhibitors, an oral immune fitness agent (IO Prime), and a discovery-stage Living Cures cargo-delivery platform. Prokarium is a therapeutics developer, not a software or data company, and publishes no public API, SDK, developer portal or machine-readable interface of any kind.
Prokarium is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunotherapy.
Prokarium’s developer surface includes engineering blog and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 1
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.